Stocks and Investing
Stocks and Investing
Tue, February 21, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Colleen Kusy Maintained (APLS) at Buy with Increased Target to $105 on, Feb 21st, 2023
Colleen Kusy of Baird, Maintained "Apellis Pharmaceuticals, Inc." (APLS) at Buy with Increased Target from $90 to $105 on, Feb 21st, 2023.
Colleen has made no other calls on APLS in the last 4 months.
There are 4 other peers that have a rating on APLS. Out of the 4 peers that are also analyzing APLS, 3 agree with Colleen's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Derek Archila of "Wells Fargo" Downgraded from Buy to Hold and Held Target at $58 on, Tuesday, January 3rd, 2023
- Chris Howerton of "Jefferies" Downgraded from Strong Buy to Hold and Decreased Target to $40 on, Thursday, November 10th, 2022
- Tiago Fauth of "Credit Suisse" Maintained at Hold with Decreased Target to $43 on, Tuesday, November 8th, 2022
This is the rating of the analyst that currently disagrees with Colleen
- Anupam Rama of "JP Morgan" Maintained at Buy with Decreased Target to $79 on, Tuesday, November 15th, 2022
Contributing Sources